Market Cap 33.65B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 11.64
Forward PE 11.39
Profit Margin 32.42%
Debt to Equity Ratio 0.90
Volume 1,446,986
Avg Vol 3,578,082
Day's Range N/A - N/A
Shares Out 575.83M
Stochastic %K 6%
Beta 0.43
Analysts Strong Sell
Price Target $61.71

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
RobertMickey186
RobertMickey186 Aug. 3 at 2:46 PM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:07 PM
0 · Reply
Alphatrades09
Alphatrades09 Jul. 29 at 2:51 PM
$RPRX 65C 8/21 @ 0.00 here
0 · Reply
Scatpack22
Scatpack22 Jul. 28 at 8:13 PM
$RPRX There’s something about these royalty companies, whether in pharma or oil & gas or gold with their massive opening margins and the revenue per employee. Gotta believe if interest rates get cut this is gonna benefit like biotechs. Time to take a position
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Jul. 24 at 7:31 PM
$RPRX printed a new 52-week high today
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF $BIOV.CSE $BVAXF is pursuing an out-licensing model, which could reduce internal commercialization requirements. The tradeoff is dependence on partner interest, deal structure and milestone execution. $LGND $RPRX $MRNA
0 · Reply
JFDI
JFDI Jul. 15 at 7:21 PM
$RPRX wow
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 4:57 PM
@Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC $RPRX $TGTX ... bio$ some new 52wk$ https://finviz.com/screener?v=211&o=-perfytd&t=DNLI%2CMIRM%2CNGNE%2CNKTX%2CPCTC%2CRPRX%2CNBIX%2CTGTX
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 2 at 2:39 PM
HIGH CONFIDENCE 🔥🚨 $RPRX 60 Call 7/17 avg .50🚨
0 · Reply
MadM
MadM Jun. 23 at 9:01 PM
$RPRX Well, it only took six years to get back. And still can't punch through that ATH ceiling.
0 · Reply
Latest News on RPRX
Royalty Pharma declares third quarter 2026 dividend

Jul 17, 2026, 4:15 PM EDT - 17 days ago

Royalty Pharma declares third quarter 2026 dividend


Royalty Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

Royalty Pharma Slides: Corporate presentation


Royalty Pharma to present at upcoming investor conferences

May 7, 2026, 4:15 PM EDT - 3 months ago

Royalty Pharma to present at upcoming investor conferences


Royalty Pharma price target raised to $58 from $50 at JPMorgan

2026-05-07T15:26:17.000Z - 3 months ago

Royalty Pharma price target raised to $58 from $50 at JPMorgan


Royalty Pharma price target raised to $66 from $50 at Citi

2026-05-07T11:16:52.000Z - 3 months ago

Royalty Pharma price target raised to $66 from $50 at Citi


Royalty Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Earnings Call Transcript: Q1 2026


Royalty Pharma Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Earnings release: Q1 2026


Royalty Pharma Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Slides: Q1 2026


Royalty Pharma Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Quarterly report: Q1 2026


Royalty Pharma reports first quarter 2026 results

May 6, 2026, 7:00 AM EDT - 3 months ago

Royalty Pharma reports first quarter 2026 results


Royalty Pharma price target raised to $57 from $51 at UBS

2026-04-21T12:29:12.000Z - 3 months ago

Royalty Pharma price target raised to $57 from $51 at UBS


Royalty Pharma Declares Second Quarter 2026 Dividend

Apr 17, 2026, 8:30 AM EDT - 3 months ago

Royalty Pharma Declares Second Quarter 2026 Dividend


Royalty Pharma Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Royalty Pharma Proxy statement: Proxy filing


Royalty Pharma Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Royalty Pharma Proxy statement: Proxy filing


Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 4 months ago

Royalty Pharma and J&J partner to develop autoimmune treatment

JNJ


Royalty Pharma Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 4 months ago

Royalty Pharma Slides: Corporate presentation


Royalty Pharma Announces Expansion of Leadership Team

Mar 17, 2026, 4:01 PM EDT - 4 months ago

Royalty Pharma Announces Expansion of Leadership Team


Royalty Pharma price target raised to $50 from $45 at TD Cowen

2026-02-27T18:55:35.000Z - 5 months ago

Royalty Pharma price target raised to $50 from $45 at TD Cowen


Royalty Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Earnings Call Transcript: Q4 2025


Royalty Pharma Annual report: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Annual report: Q4 2025


Royalty Pharma Earnings release: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Earnings release: Q4 2025


Royalty Pharma Slides: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Slides: Q4 2025


Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B

2026-02-11T12:15:33.000Z - 6 months ago

Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B


Royalty Pharma reports Q4 portfolio receipts of $874M

2026-02-11T12:06:08.000Z - 6 months ago

Royalty Pharma reports Q4 portfolio receipts of $874M


Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 6 months ago

Royalty Pharma Reports Q4 and Full Year 2025 Results


Royalty Pharma upgraded to Buy from Neutral at UBS

2026-01-30T09:45:21.000Z - 6 months ago

Royalty Pharma upgraded to Buy from Neutral at UBS


Royalty Pharma price target raised to $50 from $48 at Citi

2026-01-27T11:45:48.000Z - 6 months ago

Royalty Pharma price target raised to $50 from $48 at Citi


Royalty Pharma provides update on business performance

2026-01-12T12:36:22.000Z - 7 months ago

Royalty Pharma provides update on business performance


Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 7 months ago

Royalty Pharma Announces Dividend Increase


Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 8 months ago

Royalty Pharma to Present at Upcoming Investor Conferences


Royalty Pharma Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Royalty Pharma Earnings Call Transcript: Q3 2025


Royalty Pharma Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Royalty Pharma Quarterly report: Q3 2025


Royalty Pharma Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Royalty Pharma Earnings release: Q3 2025


Royalty Pharma Slides: Q3 2025

Nov 5, 2025, 8:00 AM EST - 9 months ago

Royalty Pharma Slides: Q3 2025


Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 9 months ago

Royalty Pharma Reports Third Quarter 2025 Results


Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 10 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend


Royalty Pharma Transcript: Investor Day 2025

Sep 11, 2025, 8:30 AM EDT - 11 months ago

Royalty Pharma Transcript: Investor Day 2025


Royalty Pharma Press release: FY 2025

Sep 11, 2025, 8:30 AM EDT - 11 months ago

Royalty Pharma Press release: FY 2025


Royalty Pharma Slides: FY 2025

Sep 11, 2025, 8:30 AM EDT - 11 months ago

Royalty Pharma Slides: FY 2025


Royalty Pharma Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Earnings Call Transcript: Q2 2025


Royalty Pharma Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Quarterly report: Q2 2025


Royalty Pharma Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Earnings release: Q2 2025


Royalty Pharma Slides: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Slides: Q2 2025


Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Royalty Pharma Reports Second Quarter 2025 Results


Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 18, 2025, 8:15 AM EDT - 1 year ago

Royalty Pharma Declares Third Quarter 2025 Dividend


RobertMickey186
RobertMickey186 Aug. 3 at 2:46 PM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:07 PM
0 · Reply
Alphatrades09
Alphatrades09 Jul. 29 at 2:51 PM
$RPRX 65C 8/21 @ 0.00 here
0 · Reply
Scatpack22
Scatpack22 Jul. 28 at 8:13 PM
$RPRX There’s something about these royalty companies, whether in pharma or oil & gas or gold with their massive opening margins and the revenue per employee. Gotta believe if interest rates get cut this is gonna benefit like biotechs. Time to take a position
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Jul. 24 at 7:31 PM
$RPRX printed a new 52-week high today
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF $BIOV.CSE $BVAXF is pursuing an out-licensing model, which could reduce internal commercialization requirements. The tradeoff is dependence on partner interest, deal structure and milestone execution. $LGND $RPRX $MRNA
0 · Reply
JFDI
JFDI Jul. 15 at 7:21 PM
$RPRX wow
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 4:57 PM
@Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC $RPRX $TGTX ... bio$ some new 52wk$ https://finviz.com/screener?v=211&o=-perfytd&t=DNLI%2CMIRM%2CNGNE%2CNKTX%2CPCTC%2CRPRX%2CNBIX%2CTGTX
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 2 at 2:39 PM
HIGH CONFIDENCE 🔥🚨 $RPRX 60 Call 7/17 avg .50🚨
0 · Reply
MadM
MadM Jun. 23 at 9:01 PM
$RPRX Well, it only took six years to get back. And still can't punch through that ATH ceiling.
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 12:17 AM
$RPRX Current Stock Price: $53.56 Contracts to trade: $52.5 RPRX Jul 17 2026 Call Entry: $1.90 Exit: $3.44 ROI: 81% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jun. 3 at 4:14 PM
HIGH CONFIDENCE 🔥🚨 $RPRX 57.5 CALL 6/18 avg .45 🚨
0 · Reply
BillionerOfKing
BillionerOfKing May. 27 at 2:21 PM
$RPRX Current Stock Price: $54.47 Contracts to trade: $55.0 RPRX Jun 18 2026 Call Entry: $0.85 Exit: $1.16 ROI: 37% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 25 at 8:23 PM
$RPRX Price: $54.50 (+1.77%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.27% RSI: 79.2 | Momentum: Moderate Volume: -18.4% vs avg Volatility: 1.11% Support: $48.89 | Resistance: $54.63 Sourch: http://marketbaubles.com/
0 · Reply
Doozio
Doozio May. 24 at 5:59 PM
$RPRX whuts gonna happen wen $XBI finally begins to $ASND ONTO 🐒🍌🧠⏰♾️
0 · Reply
CapitalMonk
CapitalMonk May. 21 at 8:40 PM
$RPRX Price: $53.55 (+0.92%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.33% RSI: 78.6 | Momentum: Moderate Volume: -25.2% vs avg Volatility: 1.09% Support: $48.89 | Resistance: $53.58 Sourch: http://marketbaubles.com/
0 · Reply
Estimize
Estimize May. 14 at 10:03 AM
Wall St is expecting 1.28 EPS for $RPRX Q2 [Reporting 08/12 BMO] http://www.estimize.com/intro/rprx?chart=historical&metric_name=eps&utm_co
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 5:04 PM
$RPRX Price: $50.15 (-0.57%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.23% RSI: 64.2 | Momentum: Moderate Volume: -54.0% vs avg Volatility: 1.05% Support: $47.44 | Resistance: $51.65 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:38 AM
$RPRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.53 down -3.64% YoY • Reported revenue of $631M up 11.04% YoY • Royalty Pharma expects 2026 Portfolio Receipts to be between $3.33B and $3.45B, an increase from previous guidance, representing expected Royalty Receipts growth of 4% to 8%.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 3 at 3:09 PM
Attached is a history of the royalty accrual $SNDX is required to record as an estimate of the amounts they will owe $RPRX over the following 12-months. Be careful to simply take the accrual & divide by 13.8% because there may be minor details around the agreement that have not been disclosed. All we know with certainty is SNDX increased the interest rate on the RPRX transaction at the end of FY25. We're not experts but it is our experience (again without knowing the exact details), by itself, the higher rate means actual Niktimvo sales have been much higher than originally forecast. Again by itself, this is a good thing for Niktimvo valuation. This is also consistent with RPRX's 9/2025 report to its shareholders that Niktimvo projected 5-year sales as of 9/2025 were 98% higher than the same 5-year projection at the time RPRX made the investment in 11/2024. $INCY sells Niktimvo As always, we could be wrong. This is not investment advice. $XBI $IBB
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 21 at 7:47 PM
$RPRX Share Price: $49.49 Contract Selected: Oct 16, 2026 $50 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.03 – $2.48 Potential Upside: 51% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply